Follow Us
https://www.thebody.com/category/hiv-policy/tag/news-analysis

The Latest

Marianne Williamson

Is Marianne Williamson's Record on AIDS as Great as She Claims?

As the 2020 presidential hopeful touts her HIV activist record, doubts remain as to whether her version of events is the full truth.

World map and rainbow flag on hands

Why We Need Pride in the Face of Worldwide Oppression, Violence, and HIV

"As we observe this Pride season," writes international HIV advocate George Ayala, "let's embrace human rights and gender equity as inherently critical prerequisites to ending the AIDS pandemic."

Gynecological chair in doctor's office

Newest Abortion Restrictions May Affect HIV Screening and Care

Creating stigma for abortions may have a chilling effect on those seeking any sexual health care.

Alexandria Ocasio-Cortez speaks with members of the PrEP4All advocacy group

Pressure Mounts on Truvada PrEP Pricing With Lawsuit and Congressional Hearings

"This isn't about you," Rep. Alexandria Ocasio-Cortez (D-NY) told Gilead CEO Daniel O'Day. "We have legislated a system that allows [this] to happen."

PrEP still life, selective focus

Will Recent Gilead Patent Concessions on Truvada Lower PrEP Prices?

Activists say this relatively small giveaway won't advance PrEP access or help end HIV in the U.S. the way a true price reduction would.

Capitol Hill

Advocates Navigate Tricky Political Terrain for Federal HIV Funding to End the U.S. Epidemic

An alliance of advocacy groups called The Partnership rallies Congress for funding while rejecting most Trump administration policies impacting the HIV community.

How Activists Uncovered CDC's Ownership of Truvada PrEP Patents Img

How Activists Uncovered CDC's Ownership of Truvada PrEP Patents

The #PrEP4All campaign made the call for affordable pre-exposure prophylaxis a national news story.

If Nobody Slashes the Price of Truvada for PrEP, What Happens Next? Img

If Nobody Slashes the Price of Truvada for PrEP, What Happens Next?

Activists and doctors say they're ready to go further if Gilead won't agree to -- or the U.S. government won't force -- a price reduction to make PrEP accessible to more Americans who need it.

Sticker Shock: PrEP Is Not Cost-Effective at Current Price, Health Economists Find Img

Sticker Shock: PrEP Is Not Cost-Effective at Current Price, Health Economists Find

But a survey reveals that about a third of black and Latino gay men would be willing to pay more than $50 per month for a prescription.

PrEP Pricing Is the Elephant in the Room at the CDC National HIV Prevention Conference Img

PrEP Pricing Is the Elephant in the Room at the CDC National HIV Prevention Conference

In a debate during a plenary session, Michael Saag, M.D., argued for more activism to make PrEP accessible to people who need it.